17 November 2015 - Although retained for use through the Cancer Drugs Fund, Roche’s breast cancer combination treatment, Kadcyla (trastuzumab emtansine), will not be recommended for routine NHS use because its price remains too high.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-kadcyla-price-still-too-high